1. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China 
Y. Zhang, P. Hu, X. Qi, H. Ren, R.-C. Mao, J.-M. Zhang 
Clinical Microbiology and Infection 
Volume 22, Issue 3, Pages 287.e1-287.e9 (March 2016)
DOI: /j.cmi
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Abbreviations: LdT, telbivudine; ETV, entecavir; NA, nucleos(t)ide analogue.
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3. Fig. 2
Effects of telbivudine (LdT) and entecavir (ETV) on hepatitis B virus (HBV) DNA and alanine transaminase (ALT) levels. (a) Cumulative rates of HBV DNA undetectability and (b) ALT normalization in telbivudine-and entecavir-treated HBV e antigen (HBeAg)-positive patients after 240 weeks.
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4. Fig. 3
Effects of telbivudine (LdT) and entecavir (ETV) on viral breakthrough. (a) The cumulative viral breakthrough rates were estimated by the Kaplan–Meier method; and (b) shown at 48, 96, 144, 192 and 240 weeks.
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

5. Fig. 4
Effects of telbivudine (LdT) and entecavir (ETV) on hepatitis B e antigen (HBeAg) seroconversion. (a)The cumulative HBeAg seroconversion rates were estimated by the Kaplan–Meier method; and (b) shown at 48, 96, 144, 192 and 240 weeks.
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

6. Fig. 5
Hepatitis B e antigen (HBeAg) seroconversion in patient sub-groups, stratified by alanine transaminase (ALT) levels. Cumulative HBeAg seroconversion rates at 48, 96, 144, 192 and 240 weeks are shown for patients who had ALT five or more times the upper limit of normal (ULN) or ALT less than five time the ULN at baseline and were treated with (a) telbivudine (LdT) or (b) entecavir (ETV).
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

7. FIG. S1. Cumulative hepatitis B e antigen (HBeAg) seroconversion rates in matched patient sub-groups. Patients matched for age, baseline serum alanine transaminase (ALT), and hepatitis B viral DNA levels were selected from the telbivudine (LDT)- and entecavir (ETV)-treated HBeAg-positive patients (n = 56 from each group). (a) Cumulative HBeAg seroconversion rates after 240 weeks, estimated by the Kaplan–Meier method; (b) cumulative HBeAg seroconversion rates at 48, 96, 144, 192 and 240 weeks.1
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

8. FIG. S2. Changes in creatine kinase (CK) and estimated glomerular filtration rate (eGFR) in patients with chronic hepatitis B (CHB) after telbivudine (LdT) and entecavir (ETV) treatment. (a) Comparison of CK elevations between the telbivudine group and entecavir group and (b) eGFR changes between the two groups.2
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

9. FIG. S3. Relationship between early virological response and cumulative hepatitis B e antigen (HBeAg) seroconversion rates at 48, 96, 144, 192 and 240 weeks in (a) the telbivudine (LdT) group or (b) the entecavir (ETV) group (early virological response: hepatitis B virus DNA <100 IU/mL at week 24 after nucleos(t)ide analogue therapy).3
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

10. FIG. S4. Relationship between early biochemical response and cumulative hepatitis B e antigen (HBeAg) seroconversion rates at 48, 96, 144, 192 and 240 weeks in (a) the telbivudine (LdT) group or (b) the entecavir (ETV) group (early biochemical response: alanine transaminase normalization at week 24 after nucleos(t)ide analogue therapy).4
Clinical Microbiology and Infection  , 287.e1-287.e9DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions